CIBC Asset Management
CYTK icon

CIBC Asset Management’s Cytokinetics CYTK Stock Holding History

CIBC Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
3,808
+621
+19% +$44.6K ﹤0.01% 1000
2026
Q1 		$210K Hold
3,187
– – ﹤0.01% 1199
2025
Q4 		$203K Buy
+3,187
New +$198K ﹤0.01% 1217
2024
Q1 		– Sell
-6,643
Closed -$555K – 1134
2023
Q4 		$555K Buy
+6,643
New +$241K ﹤0.01% 710

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Asset Management's CYTK Position: Q2 2026 in Review

CIBC Asset Management increased its Cytokinetics (CYTK) stake by 19% in Q2 2026, buying an estimated $44.6K and bringing the position to 3,808 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

CIBC Asset Management first reported a position in CYTK in Q4 2023 and has held it in 4 quarters since. The position peaked at $555K in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • CIBC Asset Management held 3,808 shares of Cytokinetics worth $324K as of Q2 2026.
  • CIBC Asset Management bought 621 Cytokinetics shares in Q2 2026, an estimated $44.6K.
  • Cytokinetics made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1000 holding.
  • CIBC Asset Management first reported a position in Cytokinetics in Q4 2023 and has held it in 4 quarters since.
  • CIBC Asset Management's Cytokinetics position peaked at $555K in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.